Ionis Stock Dip Hides Strong Drug Momentum | Business and Finance News

Ionis Pharmaceuticals’ stock took a 30% hit after a rough Q2 earnings report, but the drop masks key wins: Tryngolza got FDA approval for a broader patient group, and Dawnzera sales surged 63% sequentially. While one-time revenue from last year dragged results, core growth is intact—and management still expects full-year targets. Analysts remain bullish, seeing strong upside if Tryngolza captures new market share and Dawnzera keeps accelerating. This dip could be a buying opportunity—if Ionis executes, the next few quarters will decide its future. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/e63880f21f4ba613